ClinicalTrials.gg
CompletedNCT00981045REPAIR-IDAUpdated Feb 20, 2018Results posted

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Iron Sucrose (Venofer) in Iron Deficiency Anemia and Impaired Renal Function, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,561
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
3rd of 57
2,561 · median 100
Started
2009
with 5 others
Phase 3
16 of 57
none open now
Registered
7th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 3rd largest by enrollment, is one of 6 that started in 2009, is one of 16 in phase 3, and was the 7th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.

03

Conditions studied

  • Iron Deficiency Anemia
  • Impaired Renal Function

Keywords

  • IDA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects > or = to 18 years of age.
  • Chronically impaired renal function.
  • Screening visit central laboratory \< or = to 11.5 g/dL.
  • Screening ferritin \< or = to 100 ng/mL or \< or = to 300 when transferrin saturation (TSAT) is \< or = to 30%.
  • If on an erythropoiesis stimulating agent(ESA) a stable dose (+/- 20%) for 4 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Known reaction to any component of ferric carboxymaltose (FCM) or Venofer.
  • Previously randomized in a clinical study of Ferric Carboxymaltose (FCM).
  • Requires dialysis for treatment of chronic kidney disease OR is being considered for initiation of dialysis during the time period of this trial.
  • No evidence of iron deficiency.
  • Any non-viral infection.
  • or ALT at screening as determined by central labs greater than 1.5 times the .
  • Known positive hepatitis with evidence of active disease.
  • Received an drug within 30 days of screening.
  • Alcohol or drug abuse within the past 6 months.
  • Hemochromatosis or other iron storage disorders.
  • Estimated of less than 6 months, or for cancer patients, an Performance Status greater than 1.
  • Any other laboratory abnormality, medical condition or psychiatric disorder which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
  • Pregnant or sexually-active female subjects who are not willing to use an acceptable form of .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,561 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg

    Drug: Ferric Carboxymaltose (FCM)

  • Active comparator
    Iron Sucrose (Venofer)

    5 doses of 200 mg for a total cumulative dose of 1000 mg

    Drug: Iron Sucrose (Venofer)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.

    Time frame: Day 56

  2. Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.

    The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.

    Time frame: Day 120

07

Results

Posted Oct 18, 2013

Participant flow

04-Sept-2009 through 15-Jun-2011; Hospitals and Medical Clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Iron Sucrose (Venofer)
Started12901294
Completed12761285
Not completed149

Outcome measures

PrimaryMean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.
Time frame:
Day 56
Reported as:
Mean · g/dL
Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.
g/dLFerric Carboxymaltose (FCM)Iron Sucrose (Venofer)
Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.1.13 ± 1.0440.92 ± 0.917
PrimaryProportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.

The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.

Time frame:
Day 120
Reported as:
Number · participants
Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.
participantsFerric Carboxymaltose (FCM)Iron Sucrose (Venofer)
Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.175156

Adverse events

Collected over September 4, 2009 through June 15, 2011. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—202/1,276 (15.8%)305/1,276 (23.9%)
Iron Sucrose (Venofer)—197/1,285 (15.3%)151/1,285 (11.8%)
Most frequent serious events
Showing 10 of 218
Most frequent serious events
EventFerric Carboxymaltose (FCM)Iron Sucrose (Venofer)
Cardiac failure congestiveCardiac disorders30/127629/1285
PneumoniaInfections and infestations15/127616/1285
AnemiaBlood and lymphatic system disorders14/12764/1285
Renal failure acuteRenal and urinary disorders13/127611/1285
Acute myocardial infarctionCardiac disorders6/127611/1285
CellulitisInfections and infestations10/12766/1285
Urinary tract infectionInfections and infestations10/12762/1285
Renal failure chronicRenal and urinary disorders10/127610/1285
Gastrointestinal hemorrhageGastrointestinal disorders9/12769/1285
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders9/12767/1285
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)Iron Sucrose (Venofer)
NauseaGastrointestinal disorders172/127656/1285
HypertensionVascular disorders133/127695/1285

Baseline characteristics

14 subjects randomized to receive FCM and 9 subjects randomized to receive Venefor were randomized but discontinued prior to dosing due to subject request or selection criteria/study compliance reasons.

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)Iron Sucrose (Venofer)Total
<=18 years000
Between 18 and 65 years468500968
>=65 years8087851593
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Iron Sucrose (Venofer)Total
Mean67.5 ± 13.0067.2 ± 13.0067.3 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Iron Sucrose (Venofer)Total
Female8108181628
Male466467933
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)Iron Sucrose (Venofer)Total
United States127612852561
08

Study locations

1 site
  • Luitpold Pharmaceuticals, Inc.
    Norristown, Pennsylvania 19403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2009
First posted
Sep 22, 2009
Start
Aug 2009
Primary completionActual
Jul 2011
CompletionActual
Aug 2011
Results first posted
Oct 18, 2013
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00981045
Responsible party
Sponsor
First posted
Sep 22, 2009
Start date
Aug 2009
Primary completion
Jul 2011
Completion
Aug 2011
Results posted
Oct 18, 2013
Last update
Feb 20, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion